0.059
0.00 (0.00%)
| Penutupan Terdahulu | 0.059 |
| Jumlah Dagangan | 2,352,152 |
| Harga / Jualan (P/S) | 806.76 |
| Harga / Buku (P/B) | 5.04 |
| Julat 52 Minggu |
| Margin Keuntungan | -181.62% |
| Margin Operasi (TTM) | -49.62% |
| EPS Cair (TTM) | -0.010 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 77.00% |
| Nisbah Semasa (MRQ) | 11.24 |
| Aliran Tunai Operasi (OCF TTM) | -6.09 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.60 M |
| Pulangan Atas Aset (ROA TTM) | -45.61% |
| Pulangan Atas Ekuiti (ROE TTM) | -85.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | AROVELLA FPO [ALA] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 0.0 |
| Purata | 2.33 |
|
Arovella Therapeutics Ltd is engaged in the development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer. Its invariant Natural Killer T (iNKT) cell therapy platform is being developed as a next-generation, allogeneic off-the-shelf cell therapy platform with potential applications across blood cancers, solid tumours and selected autoimmune diseases. Its product, ALA-101, is a CD19-directed CAR-iNKT cell therapy for relapsed or refractory CD19- positive blood cancers. Arovella is expanding the platform into solid tumours through ALA-105, its CLDN18.2-targeting CAR-iNKT program for gastric and pancreatic cancers, and through incorporation of IL-12-TM armouring technology designed to enhance CARiNKT cell activity and durability. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 27.32% |
| % Dimiliki oleh Institusi | 5.29% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |